Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
10.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roivant Sciences Ltd
< Previous
1
2
3
4
5
Next >
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
June 18, 2024
Via
Benzinga
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
May 31, 2024
Via
Benzinga
ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
May 30, 2024
ROIV stock results show that Roivant Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via
InvestorPlace
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
May 22, 2024
BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million.
Via
Benzinga
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
May 07, 2024
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.
Via
InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
May 01, 2024
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.
Via
InvestorPlace
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
April 22, 2024
Via
Benzinga
Where Roivant Sciences Stands With Analysts
March 25, 2024
Via
Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
February 14, 2024
Via
Benzinga
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
April 02, 2024
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure...
Via
Benzinga
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
April 02, 2024
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
March 29, 2024
Via
Benzinga
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
March 27, 2024
Solar stocks are racking up a strong day in trading, with several of the renewable energy firms up by double-digits in Wednesday trading.
Via
Investor's Business Daily
5 Value Stocks In The Healthcare Sector
February 19, 2024
Via
Benzinga
Roivant Sciences Earnings Preview
February 12, 2024
Via
Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
January 02, 2024
Via
Benzinga
Analyst Ratings for Roivant Sciences
December 12, 2023
Via
Benzinga
8 Analysts Have This to Say About Roivant Sciences
November 14, 2023
Via
Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
Roivant Sciences Earnings Preview
November 10, 2023
Via
Benzinga
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
January 10, 2024
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to
Via
Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
December 21, 2023
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in
Via
Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
November 27, 2023
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE)
Via
Benzinga
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
October 24, 2023
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
Via
The Motley Fool
FSR Stock Alert: What to Know as Fisker Drops Prices
October 23, 2023
Fisker stock is on the move Monday as investors in FSR react to news of a price drop for one version of the company's Ocean EV.
Via
InvestorPlace
PINS Stock Pops as Stifel Upgrades Pinterest
October 23, 2023
Pinterest stock is getting a boost on Monday after a Stifel analyst upgraded PINS to a 'buy' rating and increasing its price target.
Via
InvestorPlace
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.
Via
InvestorPlace
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.